演讲人简介：

 

Carl-Henrik Heldin is since 1986 the Branch Director of the Ludwig Institute for Cancer Research in Uppsala, Sweden, and since 1992 also professor in Molecular Cell Biology at Uppsala University. He was born in 1952, and obtained a PhD degree in Medical and physiological Chemistry in 1980 at the University of Uppsala, where he continued to work until 1985 using a position sponsored by the Swedish Cancer Society.

 

The research interest of C.-H. Heldin is related to the mechanisms whereby growth factors, in particular PDGF and TGF, activate their receptors and control cell growth, migration, apoptosis and differentiation, and how perturbations of signaling pathways promote tumor progression. An aim is to explore the usefulness of signal transduction inhibitors for tumor treatment.

 

C.-H. Heldin is an elected member of the European Molecular Biology Organization (1989), Royal Swedish Academy of Sciences (1991), Royal Scientific Society (Uppsala; 1995), Academia Europea (1999), Japanese Association for Cancer Research (2002), Finnish Scientific Society (2006), ScanBalt Academy (2006), Hellenic Biochemical Society (2007), Norwegian Academy of Sciences and Letters (2009) and European Academy of Cancer Sciences (2009). He is Doctor honoris causa at the universities of Patras (2009), Helsinki (2010), Turku (2011) and Heidelberg (2011), and has obtained several awards for his work, including Prix Antoine Lacasagne (1989), the EMBO Medal (1992), K. Fernström’s Large medical prize (1993), the Meyenburg Prize (1999), the Pezcollar AACR Prize (2002), and the Honorary Medal of the Signal Transduction Society (2012).

 

C.-H. Heldin has served on the Scientific Advisory Boards for several companies and academic institutions, including European Molecular Biology Organization, Heidelberg, European Molecular Biology Laboratory, Heidelberg, German Cancer Center, Heidelberg, and Max Planck Institute for Biochemistry, Martinsried, and currently serve on the Scientific Advisory Boards for e.g. Biotechnology Center, Oslo, Center for Molecular Medicine, Vienna, Biocenter, Finland, Institute of Biomedical Technology, Tampere, and Finnish Institute for Molecular Medicine, Helsinki. He also serves as Associate Editor for Molecular Biology of the Cell, Genes to Cells and Growth Factors.

C.-H. Heldin has served on the Board of the Swedish Research Council, and is currently Vice President of the European Research Council and the Chair of the Board of the Nobel Foundation.

 

C.-H. Heldin has published 396 research articles and 201 review articles, and has 26 approved patents. His work has been cited >56,000 times and his H index is 128.